HYBRID EVENT: Join us in person in London, UK or attend virtually from anywhere.
Neonatal cholestasis is a complex medical condition characterized by the impaired flow of bile from the liver to the small intestine in infants within the first three months of life. This condition, while relatively rare, poses a significant challenge in paediatric healthcare, demanding prompt diagnosis and intervention. The underlying causes of neonatal cholestasis are diverse, encompassing a spectrum of congenital anomalies, genetic disorders, metabolic abnormalities, and infectious or inflammatory conditions. The clinical presentation often includes jaundice, pale stools, and dark urine, which are indicative of disrupted bilirubin metabolism. Timely identification of neonatal cholestasis is crucial, as prolonged cholestasis can lead to complications such as malnutrition, failure to thrive, and, in severe cases, cirrhosis. Diagnosis typically involves a comprehensive assessment of the infant's medical history, physical examination, and a battery of laboratory tests, including liver function and imaging studies. In some instances, liver biopsy may be necessary to pinpoint the underlying pathology. Management strategies vary based on the specific etiology, ranging from medical interventions to surgical procedures such as Kasai portoenterostomy for biliary atresia. Close collaboration between paediatricians, neonatologists, gastroenterologists, and surgeons is essential for the multidisciplinary approach required in the holistic care of infants with neonatal cholestasis. Advances in medical research and technology continue to refine our understanding of the diverse factors contributing to neonatal cholestasis, paving the way for improved diagnostic modalities and targeted therapeutic interventions, ultimately enhancing the prognosis and quality of life for affected infants and their families.
